Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul;23(7):885-889.
doi: 10.1038/nm.4347. Epub 2017 May 29.

Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4+ T cells

Affiliations

Novel assay reveals a large, inducible, replication-competent HIV-1 reservoir in resting CD4+ T cells

Anwesha Sanyal et al. Nat Med. 2017 Jul.

Abstract

Although antiretroviral therapy can suppress HIV-1 infection to undetectable levels of plasma viremia, integrated latent HIV-1 genomes that encode replication-competent virus persist in resting CD4+ T cells. This latent HIV-1 reservoir represents a major barrier to a cure. Currently, there are substantial efforts to identify therapeutic approaches that will eliminate or reduce the size of this latent HIV-1 reservoir. In this regard, a sensitive assay that can accurately and rapidly quantify inducible, replication-competent latent HIV-1 from resting CD4+ T cells is essential for HIV-1 eradication studies. Here we describe a reporter cell-based assay to quantify inducible, replication-competent latent HIV-1. This assay has several advantages over existing technology in that it (i) is sensitive; (ii) requires only a small blood volume; (iii) is faster, less labor intensive, and less expensive; and (iv) can be readily adapted into a high-throughput format. Using this assay, we show that the size of the inducible latent HIV-1 reservoir in aviremic participants on therapy is approximately 70-fold larger than previous estimates.

PubMed Disclaimer

Conflict of interest statement

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests in this study.

Figures

Fig. 1
Fig. 1. Sensitivity of TZM-bl cells to replication competent HIV-1
a) Acutely infected HIV-1BaL-positive CD4+ T lymphocytes (30% infection frequency as determined by flow cytometry of intracellular p24) were serially diluted with uninfected CD8+ T cell- PBMC. 1×105 cells from each serial dilution were added to 5×104 TZM-bl cells in a 96-well plate. β-gal activity was measured by chemiluminesence 48 h later. The relative light units (RLU) for the control (460,000 +/− 56,000) were subtracted from each assay sample. b) Latently HIV-1 infected ACH-2 cells were treated with 100nM PMA, serially diluted with uninfected CD8+ T cell-depleted PBMC, and added to TZM-bl cells, as described above. c) Correlation between the TCID50 for HIV-1BaL and β-gal activity in the TZM-bl cells. TZM-bl cells were infected with HIV-1BaL and β-gal activity was measured 48 h later. d) Correlation between the β-gal activity for HIV-1BaL 48 h post infection and virus production (assessed by extracellular virion associated HIV-1 RNA 10 days post-infection) e) Detection of β-gal activity in the TZM-bl cells as a function of HIV-1BaL TCID50. We observed a linear relationship between β-gal activity and TCID50 down to a TCID50 of 0.001. f) Detection of extracellular virion-associated RNA as a function of HIV-1BaL TCID50. We observed a linear relationship between extracellular virion-associated RNA and TCID50 down to a TCID50 of 1. P values (cited in the text) for c, d, e and f were obtained using the Pearson test.
Fig. 2
Fig. 2. TZM-bl cells are insensitive to infection by replication defective HIV-1
a) J-Lat clones 10.3, 9.2 and 8.4 were stimulated with PHA, serially diluted with uninfected CD8+ T cell-depleted PBMC and added to TZM-bl cells. β-gal activity was measured 48 h later. b) 8E5 cells were serially diluted with uninfected CD8+ T cell-depleted PBMC and added to TZM-bl cells. β-gal activity was measured 48 h later. c) Different p24 amounts of wild type (wt) HIV-1LAI, and a mutant virus containing the L289K mutation in reverse transcriptase that renders the enzyme defective, were added to TZM-bL cells and β-gal activity was measured 48 h later. Statistical comparison of wild type versus mutant HIV-1 β-gal activity was performed using a Student’s T test (*, P < 0.05).
Fig 3
Fig 3. TZM-bl based assay (TZA) to quantify inducible replication competent HIV-1 from rCD4+ T cells
a) Schematic overview of the TZA, b) Statistical comparison of the IUPM values determined by TZA or Q-VOA using a parametric unpaired T test (P=0061). c) Statistical comparison of fractional HIV-1 provirus expression (fPVE) determined by TZA or Q-VOA using a parametric ratio paired T test (P=0.0006). d) Correlation between TZA and total HIV-1 DNA in rCD4+ T cells. e) Correlation between Q-VOA and total HIV-1 DNA in rCD4+ T cells. f) Correlation between TZA and intracellular HIV-1 gag-pol mRNA+ cells/106 rCD4+ T cells. g) Correlation between TZA and Q-VOA. P values for all correlations were obtained using the Pearson test.
Fig. 4
Fig. 4. Relationship between β-gal RLU signal or extracellular virion-associated HIV-1 RNA and the TCID50 for HIV-1BaL
The experimental set up was same as described for Fig. 1c, 1d, 1e and 1f. The average patient RLU (n = 12) in our study was 1.8 ×106. This value closely approaches the cut-off for detection of virus production as assessed by extracellular HIV-1 RNA.

References

    1. Bailey JR, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. Journal of virology. 2006;80:6441–6457. - PMC - PubMed
    1. Finzi D, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature medicine. 1999;5:512–517. - PubMed
    1. Siliciano JD, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature medicine. 2003;9:727–728. - PubMed
    1. Lewin SR, et al. Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. Journal of virology. 1999;73:6099–6103. - PMC - PubMed
    1. Pasternak AO, et al. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PloS one. 2009;4:e8490. - PMC - PubMed